Literature DB >> 17230228

Treatment of deletion 5q acute myeloid leukemia with lenalidomide.

J E Lancet, A F List, L C Moscinski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17230228     DOI： 10.1038/sj.leu.2404526

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  6 in total

1.  Initial testing of lenalidomide by the pediatric preclinical testing program.

Authors:  C Patrick Reynolds; Min H Kang; Stephen T Keir; Richard Gorlick; E Anders Kolb; Richard Lock; John M Maris; Hernan Carol; Christopher L Morton; Catherine A Billups; Malcolm A Smith; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2011-02-25       Impact factor: 3.167

2.  A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.

Authors:  Mikkael A Sekeres; Holly Gundacker; Jeffrey Lancet; Anjali Advani; Stephen Petersdorf; Jane Liesveld; Deborah Mulford; Tom Norwood; Cheryl L Willman; Frederick R Appelbaum; Alan F List
Journal:  Blood       Date:  2011-05-06       Impact factor: 22.113

3.  Thalidomide treatment in a myelofibrosis patient with leukemia transformation.

Authors:  Wei-Han Huang; Ming-Shing Li; Sung-Chao Chu; Tso-Fu Wang; Ruey-Ho Kao; Yi-Feng Wu
Journal:  Int J Hematol       Date:  2013-12-04       Impact factor: 2.490

Review 4.  Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Amir T Fathi; Yi-Bin Chen
Journal:  Curr Hematol Malig Rep       Date:  2014-06       Impact factor: 3.952

5.  A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.

Authors:  Yiming Chen; Hagop Kantarjian; Zeev Estrov; Stefan Faderl; Farhad Ravandi; Kristy Rey; Jorge Cortes; Gautam Borthakur
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-05-10

6.  Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies.

Authors:  Lionel Ades; Thomas Prebet; Aspasia Stamatoullas; Christian Recher; Romain Guieze; Emmanuel Raffoux; Krimo Bouabdallah; Mathilde Hunault; Eric Wattel; Laure Stalnikiewicz; Andrea Toma; Hervé Dombret; Norbert Vey; Marie Sebert; Claude Gardin; Cendrine Chaffaut; Sylvie Chevret; Pierre Fenaux
Journal:  Haematologica       Date:  2016-12-29       Impact factor: 9.941
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.